Status:

RECRUITING

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Lead Sponsor:

University of Alabama at Birmingham

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Diabetes Mellitus

Cardiovascular Diseases

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Black individuals are more likely to have decreased insulin sensitivity which results in a high risk for the development of cardiometabolic disease. The reasons for this are incompletely understood. N...

Detailed Description

Black individuals are more likely to have a reduced insulin sensitivity which results in a greater risk for diabetes. However, the reasons for their decreased insulin sensitivity are not clearly under...

Eligibility Criteria

Inclusion

  • Adults: Age more than or equal to 18 years of age
  • Self-identified race/ethnicity as African-American or Black
  • Blood pressure: 120-160/80-100 mmHg

Exclusion

  • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)
  • Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)
  • BP more than 160/100 mmHg
  • BMI \>45 kg/m2
  • History of diabetes or fasting plasma glucose \>=126 mg/dL or HbA1C\>=6.5%
  • History of angioedema
  • Current or past (\<12 months) history of smoking
  • Estimated GFR \< 60 ml/min/1.73 m2; albumin-creatinine ratio ≥30 mg/g
  • Hepatic Transaminase (AST and ALT) levels \>3x the upper limit of normal
  • Significant psychiatric illness or seizure disorder
  • More than 2 Alcoholic drinks daily
  • Anemia (men, Hct \< 38%, Hb\<13 g/dL; women, Hct \<36%, Hb \<12 g/dL)
  • Inability to exercise on a treadmill

Key Trial Info

Start Date :

August 15 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 31 2027

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04055428

Start Date

August 15 2020

End Date

May 31 2027

Last Update

July 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294